End-of-day quote
Taipei Exchange
23:00:00 12/05/2024 BST
|
5-day change
|
1st Jan Change
|
25.2
TWD
|
-9.19%
|
|
-10.00%
|
+26.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,446
|
2,266
|
2,721
|
3,497
|
3,908
|
4,461
|
Enterprise Value (EV)
1 |
2,464
|
2,575
|
2,854
|
3,760
|
4,319
|
5,064
|
P/E ratio
|
-15.3
x
|
-11.3
x
|
-14.4
x
|
-34.1
x
|
-136
x
|
200
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.08
x
|
6.41
x
|
6.6
x
|
7.55
x
|
7.64
x
|
5.01
x
|
EV / Revenue
|
9.14
x
|
7.28
x
|
6.93
x
|
8.12
x
|
8.44
x
|
5.69
x
|
EV / EBITDA
|
-12.7
x
|
-17.1
x
|
-25
x
|
-45.7
x
|
347
x
|
36.4
x
|
EV / FCF
|
-19.5
x
|
-27.8
x
|
-17.7
x
|
-37.1
x
|
-387
x
|
-26.9
x
|
FCF Yield
|
-5.14%
|
-3.59%
|
-5.64%
|
-2.69%
|
-0.26%
|
-3.71%
|
Price to Book
|
2.08
x
|
2.3
x
|
2.24
x
|
3.13
x
|
3.59
x
|
2.67
x
|
Nbr of stocks (in thousands)
|
156,023
|
156,244
|
187,013
|
187,003
|
187,003
|
223,035
|
Reference price
2 |
15.68
|
14.50
|
14.55
|
18.70
|
20.90
|
20.00
|
Announcement Date
|
29/04/19
|
27/04/20
|
16/04/21
|
31/03/22
|
17/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
269.5
|
353.5
|
412
|
463.3
|
511.9
|
889.9
|
EBITDA
1 |
-194.1
|
-150.7
|
-114.3
|
-82.3
|
12.43
|
139
|
EBIT
1 |
-249.1
|
-205.4
|
-166.8
|
-133.5
|
-41.74
|
24.32
|
Operating Margin
|
-92.4%
|
-58.09%
|
-40.47%
|
-28.81%
|
-8.15%
|
2.73%
|
Earnings before Tax (EBT)
1 |
-244.7
|
-202.4
|
-165.6
|
-110.1
|
-41.11
|
22.92
|
Net income
1 |
-160.1
|
-201
|
-171.4
|
-102.7
|
-28.76
|
22.29
|
Net margin
|
-59.4%
|
-56.86%
|
-41.59%
|
-22.15%
|
-5.62%
|
2.5%
|
EPS
2 |
-1.028
|
-1.288
|
-1.012
|
-0.5489
|
-0.1538
|
0.0999
|
Free Cash Flow
1 |
-126.6
|
-92.56
|
-160.9
|
-101.3
|
-11.17
|
-188
|
FCF margin
|
-46.97%
|
-26.18%
|
-39.05%
|
-21.87%
|
-2.18%
|
-21.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/19
|
27/04/20
|
16/04/21
|
31/03/22
|
17/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
18
|
309
|
133
|
263
|
411
|
604
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.0929
x
|
-2.052
x
|
-1.166
x
|
-3.199
x
|
33.06
x
|
4.345
x
|
Free Cash Flow
1 |
-127
|
-92.6
|
-161
|
-101
|
-11.2
|
-188
|
ROE (net income / shareholders' equity)
|
-12.8%
|
-18.6%
|
-15.6%
|
-8.8%
|
-2.61%
|
1.61%
|
ROA (Net income/ Total Assets)
|
-9.79%
|
-8.32%
|
-6.3%
|
-4.76%
|
-1.44%
|
0.69%
|
Assets
1 |
1,636
|
2,415
|
2,719
|
2,158
|
1,991
|
3,234
|
Book Value Per Share
2 |
7.540
|
6.310
|
6.510
|
5.970
|
5.830
|
7.490
|
Cash Flow per Share
2 |
0.3700
|
0.2400
|
0.2700
|
0.7000
|
0.4100
|
0.3700
|
Capex
1 |
20.2
|
24
|
74.3
|
66.5
|
28.4
|
54.1
|
Capex / Sales
|
7.51%
|
6.8%
|
18.04%
|
14.36%
|
5.55%
|
6.08%
|
Announcement Date
|
29/04/19
|
27/04/20
|
16/04/21
|
31/03/22
|
17/03/23
|
15/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +26.00% | 173M | | +29.98% | 682B | | +32.16% | 586B | | -3.52% | 364B | | +18.59% | 327B | | +4.07% | 285B | | +16.45% | 240B | | +9.47% | 209B | | -9.00% | 203B | | +7.09% | 165B |
Other Pharmaceuticals
|